Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M606779200 on October 25, 2006

J. Biol. Chem., Vol. 281, Issue 52, 39831-39838, December 29, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/52/39831    most recent
M606779200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, T.
Right arrow Articles by Michael, L. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, T.
Right arrow Articles by Michael, L. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Farnesoid X Receptor Agonist Reduces Serum Asymmetric Dimethylarginine Levels through Hepatic Dimethylarginine Dimethylaminohydrolase-1 Gene Regulation*

Tonghuan Hu, Michael Chouinard, Amy L. Cox, Philip Sipes, Marialuisa Marcelo, James Ficorilli, Shuyu Li, Hong Gao, Timothy P. Ryan, M. Dodson Michael, and Laura F. Michael1

From the Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285

Received for publication, July 17, 2006 , and in revised form, September 18, 2006.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The farnesoid X receptor (FXR, NR1H4) is a bile acid-responsive nuclear receptor that plays critical roles in the transcriptional regulation genes involved in cholesterol, bile acid, triglyceride, and carbohydrate metabolism. By microarray analysis of hepatic genes from female Zucker diabetic fatty (ZDF) rats treated with the FXR agonist GW4064, we have identified dimethylarginine dimethylaminohydrolase-1 (DDAH1) as an FXR target gene. DDAH1 is a key catabolic enzyme of asymmetric dimethylarginine (ADMA), a major endogenous nitric-oxide synthase inhibitor. Sequence analysis of the DDAH1 gene reveals the presence of an FXR response element (FXRE) located 90 kb downstream of the transcription initiation site and within the first intron. Functional analysis of the putative FXRE demonstrated GW4064 dose-dependent transcriptional activation from the element, and we have demonstrated that the FXRE sequence binds the FXR-RXR heterodimer. In vivo administration of GW4064 to female ZDF rats promoted a dose-dependent and >6-fold increase in hepatic DDAH1 gene expression. The level of serum ADMA was reduced concomitantly. These findings provide a mechanism by which FXR may increase endothelium-derived nitric oxide levels through modulation of serum ADMA levels via direct regulation of hepatic DDAH1 gene expression. Thus, beneficial clinical outcomes of FXR agonist therapy may include prevention of atherosclerosis and improvement of the metabolic syndrome.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The global epidemic of obesity has led to an increasing prevalence of metabolic syndrome, a wide spectrum of metabolic risk factors characterized by abdominal obesity, low levels of high density lipoprotein cholesterol, high triglycerides, hypertension, glucose intolerance, and a systemic proinflammatory state. These risk factors are closely associated with incidence of cardiovascular disease, a leading cause of mortality in industrialized nations (1, 2). In the last decade, several ligand-activated nuclear receptors, such as peroxisome proliferator-activated receptors, liver X receptors, and thyroid hormone receptors, have emerged as promising targets for pharmacological intervention in the treatment of metabolic syndrome (3).

Nuclear receptors are transcription factors that serve as intracellular sensors for endocrine hormones and lipid metabolites, such as bile acids, fatty acids, oxysterols, and xenobiotics. To control a variety of physiological processes, receptors bind to specific cis-acting DNA elements and regulate the expression of target genes by cofactor recruitment upon activation by ligands (4). Based on their pharmacological and ligand-binding properties, the nuclear receptor superfamily can be divided into three groups (5). The first group consists of classical steroid hormone receptors that are activated by high affinity ligands. The second group comprises low affinity receptors for metabolic intermediates. The third group corresponds to orphan receptors that have no known ligands.

The farnesoid X receptor (FXR,2 NR1H4) belongs to the second group of the nuclear receptor superfamily and functions as a metabolic sensor for bile acids (6–8). FXR is primarily expressed in liver, intestine, kidney, and adrenal gland. In liver, FXR plays a critical role in the negative feedback regulation of bile acid synthesis through indirect repression of the rate-limiting enzyme cholesterol-7{alpha}-hydroxylase (CYP7A1) (9–11). FXR also regulates the expression of genes involved in bile acid homeostasis, such as bile acid transporters, bile acid synthetic enzymes, and enzymes required for detoxification (12–15). Importantly, through evaluation of FXR null mice, FXR has been shown to be involved in the regulation of lipid metabolism, as FXR-null mice display a proatherogenic lipid profile characterized by elevated cholesterol and triglyceride levels (16). Indeed, a number of genes regulating lipid metabolism, such as sterol response element binding protein, lipoprotein lipase, apolipoproteins E, AI, CII, and CIII, and scavenger receptor class B type I, are regulated by FXR (17–21). Furthermore, a growing body of evidence supports a role for FXR in carbohydrate metabolism (22–25).

Because FXR has been identified as a modulator of lipid and carbohydrate metabolism, development of a synthetic FXR agonist for treatment of dyslipidemia and diabetes, two important indicators of metabolic syndrome, appears to be an attractive therapeutic approach. The potent synthetic FXR agonist GW4064 reduces triglyceride and increases high density lipoprotein cholesterol when administrated to Fisher rats and improves insulin sensitization in genetically obese ob/ob mice and lowers blood glucose levels in diabetic db/db mice (25–27). In the present study, we have shown that GW4064 increases hepatic expression of the dimethylarginine dimethylaminohydrolase-1 (DDAH1) gene (but not DDAH2 gene) that is accompanied by a reduction in serum asymmetric dimethylarginine (ADMA), a substrate of DDAH1 enzyme (28, 29). Because ADMA is a nitric-oxide synthase (NOS) inhibitor and nitric oxide (NO) plays an important role in protection against the onset and progression of cardiovascular disease, reduction of plasma ADMA levels through FXR activation may lead to overall improvement of vascular health.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Animal Care and Treatment—Female ZDF rats were purchased from Charles River (Wilmington, MA). Animals were acclimated for one week prior to study initiation. Rats were individually housed in polycarbonate cages with filter tops. All animals received deionized water and 5008 Diet (PMI Nutrition International, Brentwood, MO) ad libitum and were maintained in accordance with the Institutional Animal Use and Care Committee of Eli Lilly and Company and the National Institutes of Health Guide for the Use and Care of Laboratory Animals. FXR agonist GW4064 was administered twice daily for nine days by oral gavage at the indicated doses (Figs. 1, 5, and 6). Animals were sacrificed, and serum and liver were collected and snap-frozen in liquid nitrogen for later use.

Microarray Analysis of Liver Gene Expression—Total RNA was isolated from ~100 mg of female ZDF rat liver tissue using TRIzol methodology (Invitrogen). RNA was further purified using RNeasyTM columns (Qiagen, Valencia, CA). Equal amounts of RNA from each animal within treatment groups were pooled (n = 6/group), and samples were prepared for GeneChipTM analysis according to the Affymetrix eukaryotic expression sample protocol revision 1 (Affymetrix, Santa Clara, CA). Samples were then hybridized to RAE230A oligonucleotide arrays. Data analysis and mining were performed using the Affymetrix Microarray Suite (MAS version 4.0) and data mining tool (DMT version 2.0) software.

Real-time PCR Analysis of Gene Expression—Real-time quantitative PCR was performed using the 5' fluorogenic nuclease assay and an ABI 7900 Prism system (PE Applied Biosystems, Foster City, CA) to determine the relative abundance of assayed mRNAs. Samples were normalized by determining the relative abundance as compared with 36B4 mRNA. Real-time quantitative PCR primer-probe sets for rat DDAH1 (Rn00574200_m1), rat SHP (Rn00589173_m1), rat PEPCK (Rn001529008_g1), rat glucose-6-phosphatase (Rn00565347_m1) and rat 36B4 (Rn00821065_g1) were obtained from Taqman Assays-on-demand Gene Expression Products (PerkinElmer Life Sciences). PCR reactions were run in quadruplicate 10-µl reactions in 384-well plates that contained Universal Master Mix (PE Applied Biosystems), 2 pmol of each forward and reverse primer, 1.5 pmol of probe, and cDNA. Data are shown as mean ± S.E.

Reporter Constructs—A 470-bp DNA sequence (90 kb downstream from the transcription initiation site) containing the conserved FXRE in the DDAH1 intron 1 region was PCR-amplified from rat genomic DNA using primers 5'-CGCCGTGTACCCAGTTTTATGTCTA-3' and 5'-CTTAATACCTCATGGATCCCGACCT-3'. The PCR product was subsequently cloned into the pGL3-tk-LUC, which contains the minimal thymidine kinase promoter (bases –105 to +51) linked to the luciferase gene. This construct was designated pGL3-tk-DDAH1 enhancer-luc. Point mutations were introduced in the FXRE using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). The primers used were 5'-CACACTTATTCCGGAATCAATGATTAATTTTAAGGGAAAC-3' and 5'-GTTTCCC TTAAAATTAATCATTGATTCCGGAATAAGTGTG-3', where the mutated bases are indicated in bold. The presence of the mutation was confirmed by automated DNA sequencing.

Transient Transfections and Luciferase Assays—Human epithelial kidney cell line HEK293T was maintained in high glucose Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. For transient transfection of HEK293 cells, 2 x 104 cells were seeded into 96-well plates and transfected using the FuGENE 6 transfection reagent (Roche Applied Science) according to the manufacturer's instructions. Each transfection contained 20 ng of luciferase reporter and 20 ng of each cytomegalovirus (CMV)-driven expression plasmid where indicated (pCMV6-FXR, pCMV6-RXR). FXR agonist GW4064 was added to the medium 24 h after transfection and incubated for another 24 h. Firefly luciferase activity in the cell extract was then measured using standard luciferase substrate reagents (BD Biosciences). All experiments were performed in triplicate and repeated at least three times. Data are shown as mean ± S.E.

Electrophoretic Mobility Shift Assays (EMSAs)—Oligonucleotides corresponding to the conserved FXRE in the DDAH1 promoter were synthesized (Operon, Huntsville, AL) as follows: wild type, 5'-ctagCTTATTCCGGGGTCAATGACCAATTTTAAGG-3' and 5'-ctagCCTTAAAATTGGTCATTGACCCCGGAATAAG-3'; mutant, 5'-CTTATTCCGGAATCAATGATTAATTTTAAGG-3' and 5'-CCTTAAAATTAATCATTGATTCCGGAATAAG-3'. The FXR/RXR binding sites are underlined and the mutations are designated in bold. Oligonucleotide pairs were resuspended in 100 mM NaCl solution, heated at 70 °C for 10 min, and annealed slowly, cooling to room temperature. Annealed oligonucleotides were radiolabeled by Klenow labeling using [{alpha}-32P]dCTP and purified using G-50 microcolumns (Amersham Biosciences). Nuclear extracts were prepared from cultured cells by the method of Dignam et al. (30). Protein concentrations were determined by a modified Bradford assay (Bio-Rad). FXR and RXR proteins were translated in vitro with the TNT T7 quick coupled transcription/translation system (Promega, Madison, WI), using full-length cDNA for FXR and RXR as DNA template. DNA-binding assays were performed as described previously (31). Nuclear protein was incubated with 15,000 cycles/min of probe in 1x EMSA buffer (final concentrations: 10 mM HEPES, pH 7.6, 75 mM KCl, 1 mM EDTA, 10% glycerol, 0.05% Triton X-100, 1 µg of poly(dI-dC)·poly(dI-dC)) for 30 min on ice. For the competition assays, the nonradiolabeled DDAH1 or IR-1 from the phospholipid transfer protein (PLTP) gene (5'-CTAGAAAACTGAGGGTCAGTGACCCAAGTGAAG-3') double-stranded oligonucleotide was added simultaneously with the labeled probe. The resulting DNA-protein complexes were resolved using 6% polyacrylamide gels with 1x TBE electrophoresis buffer (89 mM Tris base, 89 mM boric acid, 2 mM EDTA). Gels were dried and exposed to x-ray film.

ADMA/NOS Pathway Metabolite Analysis—NG,NG-Dimethyl-L-arginine (ADMA) dihydrochloride, NG,NG'-dimethl-L-arginine (SDMA) dihydrochloride NG-monomethyl-L-arginine (MMR) monoacetate were purchased from Calbiochem. Arginine, homoarginine, citrulline, and ortho-phthaldehyde were purchased from Sigma. Methanol, ammonia, and acetonitrile were of high pressure liquid chromatography grade. ADMA was analyzed as previously described by Teerlink et al. (32) with modifications. The method was cross-validated by direct quantitation using liquid chromatography-tandem mass spectrometry analysis. Briefly 100–200 µl of EDTA plasma or serum was diluted in 1x phosphate-buffered saline (Invitrogen), treated with 8 µM MMR, mixed, and loaded onto 30-mg OASIS 30-mg MCX cation exchange columns in 96-well plate format without pretreatment of solid phase. Samples were washed one time with 1 ml of 100 mM HCl followed by a second wash with 1 ml of methanol. ADMA and NOS pathway analytes were eluted twice with 0.7 ml of ammonia:water:methanol (10: 40:50). The combined eluent was dried under N2 at 60 °C in a 96-well plate evaporator. Dried samples were reconstituted in 100 µl of water and transferred to a clean plate or vials for OPA derivatization. Cross-validation samples were reconstituted in 90% acetonitrile and injected onto a 2.1 x 150-mm 5-µ Atlantis HILIC column with a 20-mm guard column (Waters, Bedford, MA). Citrulline, Arg, homoarginine, SDMA, and ADMA were eluted upon a gradient from 90% acetonitrile in 10 mM ammonium formate, 0.4% formic acid to 50% acetonitrile in 10 mM ammonium formate, and 0.4% formic acid. Multiple reaction monitoring transitions were as follows: 203.1->172.1 SDMA, 203.1->115 ADMA, 189.1->158.1 MMR, 175.1->116 Arg, and 176.1->159.1 citrulline. Study samples were derivatized with ortho-phthaldehyde as previously described (32), injected onto a 3.0 x 150-mm Luna C18 (2) column equipped with a 4-mm precolumn (Phenomenex, Torrance, CA), and eluted under isocratic conditions (8.7% acetonitrile in 50 mM potassium phosphate, pH 6.5). Detection was at excitation and emission wavelengths of 340 and 455 nm, respectively. Response factors generated from peak areas for ADMA, SDMA, homoarginine and citrulline relative to MMR were used to interpolate concentration from 8-point standard curves between 50 nM and 10 µM ADMA, ADMA, citrulline, and homoarginine and between 0.5 nM and 300 µM arginine. ADMA was expressed alone and also normalized to either SDMA or arginine. In the case of the latter, this was referred to as the NOS impairment index.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
In an attempt to study the hepatic pharmacology of FXR agonist GW4064, liver gene expression profiles from insulin-resistant female ZDF rats treated for 9 days with doses of GW4064 ranging from 10–100 mg/kg were analyzed. Pools of total RNA isolated from liver were hybridized to Affymetrix RAE230A oligonucleotide arrays representing 10,011 rat genes. An increase or decrease of 1.5-fold in mRNA levels was used as a threshold to define significant gene regulation. A total of 452 genes on the arrays exhibited significant expression changes in GW4064-treated rat livers, with the expression of 239 genes being increased and 213 genes being decreased. Identified genes displaying dose-dependent expression changes upon treatment include previously well characterized FXR target genes, such as small heterodimer partner (SHP) (10, 11), bile salt export pump (12), phosphoenolpyruvate carboxykinase (PEPCK) (22, 33), and glucose-6-phosphatase (25). In addition, expression of a novel FXR target gene, DDAH1, was elevated in a dose-dependent manner. Using quantitative real-time PCR (Q-RT-PCR), we confirmed GW4064 dose-dependent elevations of DDAH1 mRNA with a peak induction of >6-fold at the highest dose of 100 mg/kg (Fig. 1A). Similarly, the changes of gene expression in SHP, PEPCK, and glucose-6-phosphatase were also confirmed by Q-RT-PCR (Fig. 1, B–D).

To determine whether DDAH1 is a direct target gene of FXR, we aligned rat and human genome sequences using the online whole-genome navigation tool ECR Browser and identified an evolutionarily conserved region (ECR) between rat and human DDAH1 genes. Because critical regulatory elements are most likely located in the regions conserved between rodent and human, the ECRs were then scanned by the rVISTA program for FXRE sequences that are typified by an inverted repeat of the AG(G/T)TCA hexad containing a single nucleotide spacer or IR-1 element. The human DDAH1 gene region that was scanned spanned >100 kb upstream of the transcription initiation site. Three putative FXREs in the 5'-flanking region and one putative FXRE in the 108-kb intron 1 region were identified. Within the 5'-flanking region, the sequence of the putative FXRE located ~–108 kb upstream of the DDAH1 coding region is AGGTTAtAAATTC, the putative FXRE located approximately –81 kb upstream is AAGTCAaCAACCC, and the putative FXRE located approximately –19 kb upstream is ATGTTAtAAACCC. The half-sites within these putative elements resembled nuclear receptor binding sites, but they deviated from consensus core sequences. On the other hand, the intronic FXRE located 90 kb downstream of the transcription initiation site showed higher similarity to the consensus IR-1 element GGGTCAaTGACCA (Fig. 2). To generate a chimeric rat DDAH1-luciferase reporter construct, a 470-bp fragment encompassing the rat intron 1 FXRE was inserted upstream of the luciferase reporter gene (Fig. 3). The ability of FXR to transactivate luciferase expression was examined by transient transfection of this reporter construct into human epithelial kidney cell line HEK293T. In the presence of exogenously co-expressed FXR protein, the DDAH1-enhancer-luciferase reporter responded positively to GW4064 treatment in a dose-dependent manner, with a peak induction of 7-fold at the 1 µM concentration (Fig. 3A). When co-transfected with both FXR and RXR expression vectors, basal activation of the reporter was elevated by 4-fold, as compared with co-transfection with the FXR expression vector alone. GW4064 caused a dose-dependent elevation in reporter activity, resulting in 5.4-fold induction at the 1 µM concentration (Fig. 3A). This level of induction by GW4064 is consistent with the transcription induction potential that is promoted by a reporter construct containing two copies of the IR-1 sequence from the PLTP promoter linked to luciferase. This construct was activated by both FXR and RXR in a similar manner, although the maximal fold induction was 14-fold over basal (Fig. 3B). Mutation of the putative FXRE from the rat DDAH1 intron 1 reporter construct significantly reduced basal transcription levels and ablated the ability of GW4064 to induce reporter expression (Fig. 3C). Taken together, these data demonstrate that intron 1 of the rat DDAH1 genomic sequence contains a functional FXRE that has the potential to promote a transcriptional response to levels comparable with well characterized hepatic FXR target genes in the presence of an FXR agonist.


Figure 1
View larger version (22K):
[in this window]
[in a new window]

  		FIGURE 1.
Dose-dependent modulation of FXR target genes by FXR agonist GW4064. Target gene transcripts were quantified by Q-RT-PCR using RNA isolated from the liver tissue of female ZDF rats treated with either vehicle or GW4064 at the indicated doses for nine days (n = 6/group). A, expression of a novel FXR target gene, DDAH1, is elevated in rat liver by GW4064 administration. The genes known to be regulated by FXR responded dose-dependently to GW4064 (B, small heterodimer partner (SHP)); C, glucose-6-phosphatase (G6Pase); D, phosphoenolpyruvate kinase (PEPCK)). Data are normalized to the 36B4 gene and are presented as the mean ± S.E. Statistical analyses using one way analysis of variance followed by comparison with vehicle by Dunnett's method were performed.

 


Figure 2
View larger version (18K):
[in this window]
[in a new window]

  		FIGURE 2.
Identification of FXR response element in the rat DDAH1 gene. A, structure of the rat DDAH1 gene showing the sequence of the FXR response element located in intron 1. Exons are shown as solid bars, and the position of the FXR response element is shown relative to the transcription initiation site indicated by an arrow. B, comparison of FXR response element from human and rat DDAH1 genes to IR-1 elements found in the known FXR target genes small heterodimer partner (SHP), ileal bile acid-binding protein (IBABP), bile salt export pump (BSEP), fibroblast growth factors-19 and -15 (FGF19/FGF15) and a canonical IR-1 consensus sequence.

 
To determine whether FXR/RXR heterodimers bind directly to the FXRE identified in the first intron of rat DDAH1 gene, EMSAs were performed using 32P-radiolabeled oligonucleotides containing the putative FXRE. Neither FXR nor RXR alone were capable of binding to the element. When both FXR and RXR proteins were incubated together with the DNA probe, a robust FXR-RXR complex was formed with the DDAH1-FXRE (Fig. 4A). The DNA binding was effectively competed by an excess amount of either unlabeled cognate DDAH1-FXRE or the PLTP-IR-1 oligonucleotide. The DDAH1-FXRE oligonucleotide that corresponds to the reporter construct mutation could not compete for FXR-RXR binding, suggesting that the FXR/RXR heterodimer interacts specifically with the FXRE consensus site in the DDAH1 promoter. A similar result was also obtained when DDAH1-FXRE-radiolabeled oligonucleotide was incubated with HepG2 nuclear extract (Fig. 4B).

To determine whether induction of hepatic DDAH1 gene expression by FXR agonist results in modulation of circulating ADMA levels, we measured ADMA in GW4064-treated female ZDF rats using high pressure liquid chromatography with fluorescence detection methodology. Average relative recovery of serum ADMA, as measured by a modification of the method of Teerlink et al. (32), was 99.03 ± 0.09% across the dynamic range of the experiment. Coefficients of variation were 3.5% at the lower limit of quantitation (LLOQ), 0.05 µM LLOQ, and 0.53% at the upper limit of quantitation (ULOQ), 10 µM ULOQ. Precision of control samples was –5.6% at the LLOQ and 1.59% at the ULOQ. Calibration slopes averaged 0.2368 with an intercept at 0.00125 response factor, r2 = 0.9999. The method was cross-validated using HILIC high pressure liquid chromatography tandem mass spectrometry of underivatized NOS pathway metabolites.

FXR agonist treatment caused a dose-dependent decrease in serum ADMA following nine days of oral dosing. Average serum ADMA levels of vehicle-treated rats were 0.74 ± 0.017 µM. This was ~40% higher than other rat lineages studied, including Dahl salt-sensitive, Fisher 344, Sprague-Dawley, ZSF, and male diabetic ZDF rats (data not shown). Decreases in ADMA in response to the FXR agonist GW4064 ranged from 11.0% at the lowest dose to a maximum reduction of serum ADMA of 30.7% at the highest dose (Fig. 5A). Serum arginine levels in vehicle-treated animal averaged 78.3 ± 37.5 µM and were variable as might be predicted from animals consuming diet ad libitum to the point of sacrifice (Fig. 5B). Levels of arginine trended upward dose-dependently in response to FXR agonist, reaching a maximum at high dose of 173 ± 38, but the elevation was not statistically significant. To establish a ratio to describe an index of potential endothelial nitricoxide synthase (eNOS) impairment, ADMA was expressed as a function of arginine in the form of the ADMA/arginine molar ratio. Fig. 5C illustrates that the eNOS impairment ratio was significantly and dose-dependently decreased by FXR agonist by >90% at all doses. Despite the high variability within treatment groups, this reached significance at middle and high dose treatments of GW4064. Thus, FXR agonist treatment causes a dramatic decrease in the ratio of NOS inhibitor to NOS substrate. Through scatter plot display of individual animal hepatic DDAH1 and DDAH2 gene expression levels and individual serum ADMA levels, a clear correlation between serum ADMA reduction and elevated DDAH1 (but not DDAH2) gene expression resulted (Fig. 6). Collectively, these data indicate that FXR-mediated regulation of hepatic DDAH1 levels translate into lower circulating ADMA levels.


Figure 3
View larger version (29K):
[in this window]
[in a new window]

  		FIGURE 3.
Activation of the rat DDAH1 intronic enhancer sequence by FXR through the FXR response element. A schematic representation of the constructs that were utilized are shown within each panel. A 470-bp fragment encompassing the rat intron 1 FXRE was inserted upstream of the reporter gene in the pGL3-tk-Luc, which contains a minimal thymidine kinase (tk) promoter linked to the luciferase (Luc) reporter gene. The resulting construct was designated as DDAH1-enhancer-luc (wild-type). Mutations (in small bold letters) were introduced to the putative FXR response element by site-directed mutagenesis. A, dose-dependent transactivation of the wild-type DDAH1-enhancer-luc reporter gene by FXR and RXR. B, dose-dependent transactivation of positive control 2XIR-1-luc reporter gene by FXR and RXR. C, mutation of the putative FXR response element in the rat DDAH1 promoter abolishes transactivation activity. All experiments were performed in triplicate and repeated at least three times. Data are shown as mean ± S.E. R.L.U., relative light units.

 


Figure 4
View larger version (56K):
[in this window]
[in a new window]

  		FIGURE 4.
Binding of FXR-RXR heterodimers to the intronic DDAH1 FXR response element. A, EMSAs using in vitro translated FXR and RXR proteins. DNA-protein complexes were formed between in vitro translated FXR and RXR protein and the FXR response element from the DDAH1 intronic region. The interaction was competed specifically by excess amount (100x) of unlabeled wild-type (DDAH1) or IR-1 but not mutant (DDAH1m) oligonucleotides. B, EMSA result using HepG2 nuclear extracts (HepG2 NE). n.s., nonspecific binding.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, we have identified DDAH1 as a direct target gene of FXR in liver. Two isoforms of DDAH, DDAH1 and DDAH2, share similar gene structure and enzyme activity but display distinct tissue distributions. DDAH1 is found predominantly in tissues expressing neuronal NOS and in peripheral tissues such as liver, adrenal gland, testis, and kidney, whereas DDAH2 is found predominantly in tissues expressing endothelial NOS and inducible NOS, such as heart and aorta (34, 35).

Dimethylarginines originate from the degradation of methylated proteins. Methylation of arginine residues is catalyzed by protein arginine methyltransferases, giving rise to three forms of methylarginines, N-monomethyl-arginine, asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA) (36). Proteolytic catabolism of arginine-methylated proteins releases free methylarginine. N-Monomethyl-arginine and ADMA (but not SDMA) act as inhibitors of NOS by competing with the substrate of the enzyme arginine (37, 38). In the cardiovascular system, nitric oxide that is generated from endothelium acts as an endogenous anti-atherosclerotic molecule by inducing vasodilatation, inhibiting the adhesion of platelets and white blood cells, suppressing vascular smooth muscle cell proliferation, and reducing vascular production of superoxide radicals (37).


Figure 5
View larger version (16K):
[in this window]
[in a new window]

  		FIGURE 5.
FXR regulates serum ADMA and arginine levels. A, serum ADMA levels in female ZDF rats treated orally with GW4064 for nine days. Average ADMA levels for each group are shown (n = 6, ±S.E.). Analysis of variance by Student-Newman-Keuls showed all comparisons were significant (p < 0.02). B, serum arginine levels in female ZDF rats treated orally with GW4064 for nine days. Average levels for each group are shown (n = 6, ±S.E.). None of the comparisons were statistically significant. C, expression of the eNOS impairment index is described as ADMA/arginine molar ratio, which reflects the eNOS inhibitor to substrate ratio. Treatment group averages (shown ±S.E.) varied as a function of arginine variability; however, significance was observed based on Mann-Whitney rank sum comparison (p < 0.05).

 


Figure 6
View larger version (16K):
[in this window]
[in a new window]

  		FIGURE 6.
FXR agonist dose-dependent correlation of liver DDAH1 (but not DDAH2) expression with serum ADMA levels in GW4064-treated female ZDF rats. Closed (DDAH1) and open (DDAH2) symbols represent vehicle (•), 10 ({blacktriangledown}), 30 ({blacksquare}), and 100 ({diamondsuit}) mg/kg GW4064 treatment for nine days.

 
Elevated plasma ADMA levels are associated with reduced nitric oxide synthesis and are detected in the human plasma of several clinical conditions, including hypercholesterolemia, hypertriglyceridemia, hypertension, type II diabetes, chronic renal failure, and chronic heart failure, implicating ADMA as a marker of cardiovascular risk (37, 39–43). Because ADMA is generated constantly in the course of normal protein turnover, two known mechanisms prevent its accumulation in the body and eliminate potential detrimental effects on vascular tone and structure. One mechanism occurs through renal excretion of ADMA and the other mechanism is through conversion to citrulline and methyamines by the action of DDAH (42). Indeed, overexpression of human DDAH1 in transgenic mice results in a 2-fold increase in NOS activity and nitric oxide production that is associated with 2-fold reduction in plasma ADMA (44, 45).

Here, we have discovered that administration of the FXR agonist GW4064 to female ZDF rats leads to dose-dependent activation of DDAH1 (but not DDAH2) gene expression in liver. The induction of DDAH1 gene expression is highly correlated with the reduction of serum ADMA levels, indicating that liver may be a major site for elimination of ADMA through the action of DDAH1. In agreement, previous reports suggest that the liver likely plays an important role in the metabolism of ADMA by taking up large amounts of ADMA from the systemic circulation (46–48). Other nuclear receptor agonists, such as the PPAR{alpha} agonist fenofibrate, influence serum arginine levels without modulation of ADMA levels; whereas, both arginine and ADMA are influenced in opposite directions by rosiglitazone and all-trans-retinoic acid (41, 49, 50). As the endogenous eNOS inhibitor ADMA is lowered by FXR agonist treatment, we show a corresponding trend toward increasing arginine levels in a dose-dependent manner (Fig. 5). In fact, the benefit of increasing arginine alone in rescuing metabolic dysfunction phenotypes has been shown previously (51). Thus, it is plausible that fenofibrate, glitazones, and FXR-mediated trends in elevating serum arginine alone could play a role in improving metabolic dysfunction. On the other hand, increases in arginine that are accompanied by decreases in ADMA levels can be expressed as an index of potential NOS impairment. Accordingly, as arginine levels increase and ADMA levels decrease, the index may be reflective of the FXR influence on the metabolic rate of eNOS. The decrease in ADMA in response to FXR correlates with the relative hepatic gene expression of DDAH1 but not with that of DDAH2 (Fig. 6), suggesting that the primary clearance of ADMA from the vascular compartment may be through FXR-mediated hepatic gene expression of DDAH1 and consequent metabolism of ADMA.

An FXRE was identified in the intron I region of the DDAH1 gene that is conserved among human, dog, rat, and mouse. A luciferase reporter construct driven by a DDAH1 gene intronic enhancer fragment containing the FXRE site linked to the thymidine kinase basal promoter responded to GW4064 in a dose-dependent manner in the presence of co-transfection of FXR and RXR expression plasmid. This response was completely abolished when the FXRE site was mutated by site-directed mutagenesis, suggesting that the activation was through the FXRE site. Furthermore, the EMSA results confirmed that FXR/RXR heterodimer bind directly to the DDAH1-FXRE site in a similar manner as a previously well characterized PLTP-IR-1 site.

Although a putative FXRE site was also identified in the proximal 5' upstream region of the rat DDAH2 gene, no agonist-responsive transcriptional activation was observed with a DDAH2 promoter-reporter construct, consistent with Q-RT-PCR analysis of DDAH2 gene expression from the in vivo study (data not shown and Fig. 6). DDAH2 expression has been reported to be induced by all-trans-retinoic acid treatment with increased nitric oxide synthesis in endothelial cells (49), suggesting that DDAH1 and DDAH2 may be regulated by differential tissue-specific factors.

A recent study showed that FXR is expressed in the vascular smooth muscle cells both in vitro and in vivo (52). Our study provides evidence for the first time that FXR may play an important role in the preservation of vascular health, not only by regulation of lipid metabolism, but also by modulation of ADMA and consequently nitric oxide levels through the regulation of liver DDAH1 expression.


   FOOTNOTES
 
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Cardiovascular Research, Eli Lilly and Company, DC0520, Indianapolis, IN 46285. Tel.: 317-433-9468; Fax: 317-433-2815; E-mail: laura_michael{at}lilly.com.

2 The abbreviations used are: FXR, farnesoid X receptor; FXRE, FXR response element; DDAH1, dimethylarginine dimethylaminohydrolase-1; ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine; NOS, nitric-oxide synthase; eNOS, endothelial nitric-oxide synthase; PEPCK, phosphoenolpyruvate carboxykinase; SHP, small heterodimer partner; EMSA, electrophoretic mobility shift assay; MMR, monomethyl-L-arginine; IR, inverted repeat; PLTP, phospholipid transfer protein; LLOQ, lower limit of quantitation; ULOQ, upper limit of quantitation; Q-RT-PCR, quantitative real-time-PCR; HILIC, hydrophilic interaction chromatography. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Eckel, R. H., Grundy, S. M., and Zimmet, P. Z. (2005) Lancet 365, 1415–1428[CrossRef][Medline] [Order article via Infotrieve]
  2. Grundy, S. M. (2006) Nat. Rev. Drug Discov. 5, 295–309[CrossRef][Medline] [Order article via Infotrieve]
  3. Shulman, A. I., and Mangelsdorf, D. J. (2005) N. Engl. J. Med. 353, 604–615[Free Full Text]
  4. Kalaany, N. Y., and Mangelsdorf, D. J. (2006) Annu. Rev. Physiol. 68, 159–191[CrossRef][Medline] [Order article via Infotrieve]
  5. Berkenstam, A., and Gustafsson, J. A. (2005) Curr. Opin. Pharmacol. 5, 171–176[CrossRef][Medline] [Order article via Infotrieve]
  6. Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., and Shan, B. (1999) Science 284, 1362–1365[Abstract/Free Full Text]
  7. Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., and Lehmann, J. M. (1999) Science 284, 1365–1368[Abstract/Free Full Text]
  8. Russell, D. W. (1999) Cell 97, 539–542[CrossRef][Medline] [Order article via Infotrieve]
  9. Chiang, J. Y., Kimmel, R., Weinberger, C., and Stroup, D. (2000) J. Biol. Chem. 275, 10918–10924[Abstract/Free Full Text]
  10. Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., Maloney, P. R., Willson, T. M., and Kliewer, S. A. (2000) Mol. Cell 6, 517–526[CrossRef][Medline] [Order article via Infotrieve]
  11. Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., and Mangelsdorf, D. J. (2000) Mol. Cell 6, 507–515[CrossRef][Medline] [Order article via Infotrieve]
  12. Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D. J., and Suchy, F. J. (2001) J. Biol. Chem. 276, 28857–28865[Abstract/Free Full Text]
  13. Grober, J., Zaghini, I., Fujii, H., Jones, S. A., Kliewer, S. A., Willson, T. M., Ono, T., and Besnard, P. (1999) J. Biol. Chem. 274, 29749–29754[Abstract/Free Full Text]
  14. Huang, L., Zhao, A., Lew, J. L., Zhang, T., Hrywna, Y., Thompson, J. R., de Pedro, N., Royo, I., Blevins, R. A., Pelaez, F., Wright, S. D., and Cui, J. (2003) J. Biol. Chem. 278, 51085–51090[Abstract/Free Full Text]
  15. Yu, L., Gupta, S., Xu, F., Liverman, A. D., Moschetta, A., Mangelsdorf, D. J., Repa, J. J., Hobbs, H. H., and Cohen, J. C. (2005) J. Biol. Chem. 280, 8742–8747[Abstract/Free Full Text]
  16. Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., and Gonzalez, F. J. (2000) Cell 102, 731–744[CrossRef][Medline] [Order article via Infotrieve]
  17. Claudel, T., Inoue, Y., Barbier, O., Duran-Sandoval, D., Kosykh, V., Fruchart, J., Fruchart, J. C., Gonzalez, F. J., and Staels, B. (2003) Gastroenterology 125, 544–555[CrossRef][Medline] [Order article via Infotrieve]
  18. Claudel, T., Sturm, E., Duez, H., Torra, I. P., Sirvent, A., Kosykh, V., Fruchart, J. C., Dallongeville, J., Hum, D. W., Kuipers, F., and Staels, B. (2002) J. Clin. Investig. 109, 961–971[CrossRef][Medline] [Order article via Infotrieve]
  19. Kast, H. R., Nguyen, C. M., Sinal, C. J., Jones, S. A., Laffitte, B. A., Reue, K., Gonzalez, F. J., Willson, T. M., and Edwards, P. A. (2001) Mol. Endocrinol. 15, 1720–1728[Abstract/Free Full Text]
  20. Malerod, L., Sporstol, M., Juvet, L. K., Mousavi, S. A., Gjoen, T., Berg, T., Roos, N., and Eskild, W. (2005) Biochem. Biophys. Res. Commun. 336, 1096–1105[CrossRef][Medline] [Order article via Infotrieve]
  21. Prieur, X., Coste, H., and Rodriguez, J. C. (2003) J. Biol. Chem. 278, 25468–25480[Abstract/Free Full Text]
  22. Cariou, B., van Harmelen, K., Duran-Sandoval, D., van Dijk, T., Grefhorst, A., Bouchaert, E., Fruchart, J. C., Gonzalez, F. J., Kuipers, F., and Staels, B. (2005) FEBS Lett. 579, 4076–4080[CrossRef][Medline] [Order article via Infotrieve]
  23. Claudel, T., Staels, B., and Kuipers, F. (2005) Arterioscler. Thromb. Vasc. Biol. 25, 2020–2030[Abstract/Free Full Text]
  24. Ma, K., Saha, P. K., Chan, L., and Moore, D. D. (2006) J. Clin. Investig. 116, 1102–1109[CrossRef][Medline] [Order article via Infotrieve]
  25. Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., and Edwards, P. A. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 1006–1011[Abstract/Free Full Text]
  26. Cariou, B., van Harmelen, K., Duran-Sandoval, D., van Dijk, T. H., Grefhorst, A., Abdelkarim, M., Caron, S., Torpier, G., Fruchart, J. C., Gonzalez, F. J., Kuipers, F., and Staels, B. (2006) J. Biol. Chem. 281, 11039–11049[Abstract/Free Full Text]
  27. Willson, T. M., Jones, S. A., Moore, J. T., and Kliewer, S. A. (2001) Med. Res. Rev. 21, 513–522[CrossRef][Medline] [Order article via Infotrieve]
  28. Ogawa, T., Kimoto, M., and Sasaoka, K. (1987) Biochem. Biophys. Res. Commun. 148, 671–677[CrossRef][Medline] [Order article via Infotrieve]
  29. Ogawa, T., Kimoto, M., and Sasaoka, K. (1989) J. Biol. Chem. 264, 10205–10209[Abstract/Free Full Text]
  30. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475–1489[Abstract/Free Full Text]
  31. Scott, G. K., Daniel, J. C., Xiong, X., Maki, R. A., Kabat, D., and Benz, C. C. (1994) J. Biol. Chem. 269, 19848–19858[Abstract/Free Full Text]
  32. Teerlink, T., Nijveldt, R. J., de Jong, S., and van Leeuwen, P. A. (2002) Anal. Biochem. 303, 131–137[CrossRef][Medline] [Order article via Infotrieve]
  33. Stayrook, K. R., Bramlett, K. S., Savkur, R. S., Ficorilli, J., Cook, T., Christe, M. E., Michael, L. F., and Burris, T. P. (2005) Endocrinology 146, 984–991[Abstract/Free Full Text]
  34. Leiper, J., and Vallance, P. (1999) Cardiovasc. Res. 43, 542–548[Abstract/Free Full Text]
  35. Tran, C. T., Fox, M. F., Vallance, P., and Leiper, J. M. (2000) Genomics 68, 101–105[CrossRef][Medline] [Order article via Infotrieve]
  36. Vallance, P., and Leiper, J. (2004) Arterioscler. Thromb. Vasc. Biol. 24, 1023–1030[Abstract/Free Full Text]
  37. Boger, R. H. (2003) Cardiovasc. Res. 59, 824–833[CrossRef][Medline] [Order article via Infotrieve]
  38. Vallance, P., and Leiper, J. (2002) Nat. Rev. Drug Discov. 1, 939–950[CrossRef][Medline] [Order article via Infotrieve]
  39. Mallamaci, F., Tripepi, G., Maas, R., Malatino, L., Boger, R., and Zoccali, C. (2004) J. Am. Soc. Nephrol. 15, 435–441[Abstract/Free Full Text]
  40. Ravani, P., Tripepi, G., Malberti, F., Testa, S., Mallamaci, F., and Zoccali, C. (2005) J. Am. Soc. Nephrol. 16, 2449–2455[Abstract/Free Full Text]
  41. Stuhlinger, M. C., Abbasi, F., Chu, J. W., Lamendola, C., McLaughlin, T. L., Cooke, J. P., Reaven, G. M., and Tsao, P. S. (2002) J. Am. Med. Assoc. 287, 1420–1426[Abstract/Free Full Text]
  42. Tran, C. T., Leiper, J. M., and Vallance, P. (2003) Atheroscler. Suppl. 4, 33–40[Medline] [Order article via Infotrieve]
  43. Zoccali, C., and Kielstein, J. T. (2006) Curr. Opin. Nephrol. Hypertens. 15, 314–320[Medline] [Order article via Infotrieve]
  44. Dayoub, H., Achan, V., Adimoolam, S., Jacobi, J., Stuehlinger, M. C., Wang, B. Y., Tsao, P. S., Kimoto, M., Vallance, P., Patterson, A. J., and Cooke, J. P. (2003) Circulation 108, 3042–3047
  45. Jacobi, J., Sydow, K., von Degenfeld, G., Zhang, Y., Dayoub, H., Wang, B., Patterson, A. J., Kimoto, M., Blau, H. M., and Cooke, J. P. (2005) Circulation 111, 1431–1438
  46. Carello, K. A., Whitesall, S. E., Lloyd, M. C., Billecke, S. S., and D'Alecy, L. G. (2006) Am. J. Physiol. 290, H209–H216
  47. Nijveldt, R. J., Teerlink, T., Siroen, M. P., van Lambalgen, A. A., Rauwerda, J. A., and van Leeuwen, P. A. (2003) Clin. Nutr. 22, 17–22[Medline] [Order article via Infotrieve]
  48. Siroen, M. P., van der Sijp, J. R., Teerlink, T., van Schaik, C., Nijveldt, R. J., and van Leeuwen, P. A. (2005) Hepatology 41, 559–565[CrossRef][Medline] [Order article via Infotrieve]
  49. Achan, V., Tran, C. T., Arrigoni, F., Whitley, G. S., Leiper, J. M., and Vallance, P. (2002) Circ. Res. 90, 764–769[Abstract/Free Full Text]
  50. Dierkes, J., Westphal, S., Martens-Lobenhoffer, J., Luley, C., and Bode-Boger, S. M. (2004) Atherosclerosis 173, 239–244[CrossRef][Medline] [Order article via Infotrieve]
  51. Huynh, N. T., and Tayek, J. A. (2002) J. Am. Coll. Nutr. 21, 422–427[Abstract/Free Full Text]
  52. Bishop-Bailey, D., Walsh, D. T., and Warner, T. D. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 3668–3673[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Physiol. Rev.Home page
P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Physiol Rev, January 1, 2009; 89(1): 147 - 191.
[Abstract] [Full Text] [PDF]

Home page
 JPEN J Parenter Enteral NutrHome page
M. C. Richir, R. H. Bouwman, T. Teerlink, M. P.C. Siroen, T. P.G.M. de Vries, and P. A.M. van Leeuwen
The Prominent Role of the Liver in the Elimination of Asymmetric Dimethylarginine (ADMA) and the Consequences of Impaired Hepatic Function
JPEN J Parenter Enteral Nutr, November 1, 2008; 32(6): 613 - 621.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. T. Kielstein and C. Zoccali
A New Perspective for the Treatment of Renal Diseases?
J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1365 - 1367.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/52/39831    most recent
M606779200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, T.
Right arrow Articles by Michael, L. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, T.
Right arrow Articles by Michael, L. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement